Startups
Deciduous Therapeutics
Edit

Deciduous Therapeutics

https://www.deciduoustx.com/
Last activity: 27.10.2021
Active
Categories: BioTechLocalResearch
Senescent cells, which are characterized by irreversible damage and an inflammatory secretome, are considered a key driving force behind many age-related diseases. Due to a failure in immune surveillance, senescent cells accumulate and impact their local environment by inducing inflammation and promoting extracellular matrix remodeling, thus resulting in a myriad of metabolic and fibrotic consequences. Therefore, enabling the removal of senescent cells dramatically ameliorates disease pathologies in many age-related diseases, leading to overall improvements in health-span.

At Deciduous Therapeutics, we have discovered novel molecules that can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells and thereby treat several classes of age-related diseases.
Followers
708
Mentions
1

Overview

Location
United States, California, San Francisco
Employees
11-50

Investors 5

Mentions in press and media 1

DateTitleDescription
Sign up to seeSign up to seeSign up to see

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Deciduous Therapeutics

Who has invested in Deciduous Therapeutics?

Parsers VC lists 5 investors of Deciduous Therapeutics, among them Healthspan Capital, age1 and quadraScope Ventures.

Is Deciduous Therapeutics still active?

Yes, Deciduous Therapeutics is active; its latest activity on Parsers VC dates from Oct 27, 2021.